anti ulcer agents

Summary

Summary: Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.

Top Publications

  1. ncbi The biochemistry and medical significance of the flavonoids
    Bent H Havsteen
    Department of Biochemistry, University of Kiel, Olshausenstrasse 40, D 24098, Kiel, Germany
    Pharmacol Ther 96:67-202. 2002
  2. ncbi Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection
    M Hojo
    Dept. of Gastroenterology, Juntendo University, School of Medicine, Tokyo, Japan
    Scand J Gastroenterol 36:690-700. 2001
  3. ncbi Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole
    David Y Graham
    Veterans Affairs Medical Center 111D, 2002 Holcombe Blvd, Room 3A 320, Houston, TX 77030 4211, USA
    Arch Intern Med 162:169-75. 2002
  4. ncbi Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis
    Richard J Saad
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
    Am J Gastroenterol 101:488-96. 2006
  5. ncbi Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers
    Clive H Wilder-Smith
    Gastrointestinal Unit and Gastrointestinal Physiology Laboratory, Bern, Switzerland
    Digestion 68:184-8. 2003
  6. ncbi Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin
    H Kawabata
    Department of Gastroenterology, Kyoto Second Red Cross Hospital, Japan
    Aliment Pharmacol Ther 17:259-64. 2003
  7. ncbi A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy
    Laurence Maiden
    Department of Medicine, Guy s, King s, St Thomas Medical School, London, England
    Gastroenterology 128:1172-8. 2005
  8. ncbi Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens
    S Michopoulos
    Gastroenterology Unit, Alexandra University Hospital, Athens, Greece
    Aliment Pharmacol Ther 14:737-44. 2000
  9. ncbi Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial
    E Bolling-Sternevald
    Dept of Biomedicine, Linkoping, Sweden
    Scand J Gastroenterol 37:1395-402. 2002
  10. ncbi Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study
    Philip Miner
    Oklahoma Foundation for Digestive Research, University of Oklahoma Health Sciences Center, 711 Stanton L Young Boulevard, Suite 619, Oklahoma City, OK 73104, USA
    Am J Gastroenterol 98:2616-20. 2003

Detail Information

Publications233 found, 100 shown here

  1. ncbi The biochemistry and medical significance of the flavonoids
    Bent H Havsteen
    Department of Biochemistry, University of Kiel, Olshausenstrasse 40, D 24098, Kiel, Germany
    Pharmacol Ther 96:67-202. 2002
    ....
  2. ncbi Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection
    M Hojo
    Dept. of Gastroenterology, Juntendo University, School of Medicine, Tokyo, Japan
    Scand J Gastroenterol 36:690-700. 2001
    ..The strategy of adding two new antimicrobials to previous regimens was also effective in re-eradication therapy...
  3. ncbi Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole
    David Y Graham
    Veterans Affairs Medical Center 111D, 2002 Holcombe Blvd, Room 3A 320, Houston, TX 77030 4211, USA
    Arch Intern Med 162:169-75. 2002
    ....
  4. ncbi Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis
    Richard J Saad
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
    Am J Gastroenterol 101:488-96. 2006
    ..Levofloxacin-based triple therapy has been suggested as an alternative salvage therapy to bismuth-based quadruple therapy for persistent Helicobacter pylori (H. pylori) infection...
  5. ncbi Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers
    Clive H Wilder-Smith
    Gastrointestinal Unit and Gastrointestinal Physiology Laboratory, Bern, Switzerland
    Digestion 68:184-8. 2003
    ..To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers...
  6. ncbi Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin
    H Kawabata
    Department of Gastroenterology, Kyoto Second Red Cross Hospital, Japan
    Aliment Pharmacol Ther 17:259-64. 2003
    ..To investigate the effect of different proton pump inhibitors, S-mephenytoin 4'-hydroxylase (CYP2C19) genotype and antibiotic susceptibility on the eradication rate of Helicobacter pylori...
  7. ncbi A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy
    Laurence Maiden
    Department of Medicine, Guy s, King s, St Thomas Medical School, London, England
    Gastroenterology 128:1172-8. 2005
    ..We used wireless capsule enteroscopy to quantitate and assess the nature of the small bowel damage caused by nonsteroidal anti-inflammatory drugs when taken on a short-term basis...
  8. ncbi Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens
    S Michopoulos
    Gastroenterology Unit, Alexandra University Hospital, Athens, Greece
    Aliment Pharmacol Ther 14:737-44. 2000
    ..Few data are available on the efficacy of second-line H. pylori eradication regimens...
  9. ncbi Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial
    E Bolling-Sternevald
    Dept of Biomedicine, Linkoping, Sweden
    Scand J Gastroenterol 37:1395-402. 2002
    ..The role of drug treatment remains controversial. The aim in this study was to evaluate the effect of omeprazole 20 mg twice daily (b.i.d) and to test methods for symptom assessment...
  10. ncbi Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study
    Philip Miner
    Oklahoma Foundation for Digestive Research, University of Oklahoma Health Sciences Center, 711 Stanton L Young Boulevard, Suite 619, Oklahoma City, OK 73104, USA
    Am J Gastroenterol 98:2616-20. 2003
    ..The objective of this study was to evaluate and compare intragastric pH following standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole...
  11. ncbi Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders
    Susan M Cheer
    Adis International Limited, Miarangi Bay, Auckland, New Zealand
    Drugs 63:101-33. 2003
    ..Thus, pantoprazole is a valuable alternative to other PPIs in the treatment of acid-related disorders...
  12. pmc Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group
    N J Talley
    Department of Medicine, University of Sydney, Nepean Hospital, Penrith, New South Wales 2751, Australia
    BMJ 318:833-7. 1999
    ..To determine whether eradication of Helicobacter pylori relieves the symptoms of functional dyspepsia...
  13. ncbi Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report
    P Malfertheiner
    Center for Internal Medicine, Clinic of Gastroenterology, Otto von Guericke University of Magdeburg, Leipziger Strasse 44, D 39120 Magdeburg, Germany
    Aliment Pharmacol Ther 16:167-80. 2002
    ..Successful eradication should always be confirmed by urea breath test or an endoscopy-based test if endoscopy is clinically indicated. Stool antigen test is the alternative if urea breath test is not available...
  14. ncbi Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors
    F Buttgereit
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, Humboldt University, FB, GRB, Berlin, Germany
    Am J Med 110:13S-9S. 2001
    ..Finally, we offer recommendations on the clinical use of these drugs, emphasizing the need to balance clinical effectiveness with the avoidance of potential gastrointestinal side effects...
  15. ncbi Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury
    S Sartori
    Divisione di Medicina Interna e Oncologia Medica, Azienda Ospedaliera S Anna, Italy
    J Clin Oncol 18:463-7. 2000
    ..Anticancer drugs may induce acute mucosal injury to stomach and duodenum. This study was planned to evaluate the efficacy of omeprazole or ranitidine in preventing such an injury...
  16. ncbi The clinical role of cytochrome p450 genotypes in Helicobacter pylori management
    A Sapone
    Department of Pharmacology, Pharmacogenomic Unit St Orsola Hospital, University of Bologna, Bologna, Italy
    Am J Gastroenterol 98:1010-5. 2003
    ..The aim of this pharmacogenomics study was to investigate the influence of different cytochrome P450 (CYP) genotypes in Helicobacter pylori eradication therapy...
  17. ncbi Retreatment of Helicobacter pylori infection after initial treatment failure
    D J Kearney
    Gastroenterology Section, University of Washington, VA Puget Sound Health Care System, Seattle, USA
    Am J Gastroenterol 96:1335-9. 2001
    ..CONCLUSION: Further studies are needed to better define the optimal second treatment regimen after failed H. pylori treatment...
  18. ncbi Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem
    U Klotz
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Int J Clin Pharmacol Ther 44:297-302. 2006
    ..Thus, a genotype-adjusted dosage regimen will improve therapeutic efficacy of PPIs...
  19. ncbi Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms
    Kerstin Röhss
    Experimental Medicine, AstraZeneca R and D Molndal, Pepparedsleden 1, 431 83, Molndal, Sweden
    Eur J Clin Pharmacol 60:531-9. 2004
    ....
  20. ncbi Recent advances in the treatment of GERD in the elderly: focus on proton pump inhibitors
    A Pilotto
    IRCCS, Casa Sollievo della Sofferenza, Istituto di Ricovero e Cura a Carattere Scientifico, San Giovanni Rotondo, Italy
    Int J Clin Pract 59:1204-9. 2005
    ..In addition, the PPIs seem to be safe both in short- and in long-term therapy of elderly patients with GERD...
  21. ncbi Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study
    H H Tsai
    Castle Hill Hospital, Cottingham, Hull, UK
    Aliment Pharmacol Ther 20:657-65. 2004
    ..Symptom relief, through adherence to appropriate maintenance therapy, is the sole objective of treatment for patients with endoscopy-negative gastro-oesophageal reflux disease...
  22. ncbi Review article: drug interactions with agents used to treat acid-related diseases
    T J Humphries
    Eisai Ltd, London, UK
    Aliment Pharmacol Ther 13:18-26. 1999
    ..These differences are important when choosing medications for the safe treatment of patients with acid-related diseases...
  23. ncbi Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies
    F K Chan
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong
    Aliment Pharmacol Ther 14:91-5. 2000
    ..Salvage therapies after initial Helicobacter pylori eradication failure of ranitidine bismuth citrate (RBC)-based regimens remain undefined...
  24. ncbi Standardization of surgical technique in antireflux surgery: the LOTUS Trial experience
    Stephen E A Attwood
    Department of Surgery, Northumbria Healthcare, North Tyneside Hospital, Rake Lane, North Shields, NE29 8NH, United Kingdom
    World J Surg 32:995-8. 2008
    ..This study was designed to identify a methodology for standardization of surgical technique and to measure the effectiveness of this standardization...
  25. ncbi Underutilization of preventive strategies in patients receiving NSAIDs
    M C J M Sturkenboom
    Department of Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands
    Rheumatology (Oxford) 42:iii23-31. 2003
    ....
  26. ncbi Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate
    H Fakheri
    Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
    Aliment Pharmacol Ther 15:411-6. 2001
    ..OABF is a good alternative in the face of growing resistance to clarithromycin in developed countries, and is attractive for developing countries where clarithromycin is not readily available...
  27. ncbi Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer
    G Javid
    Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar 190001, Kashmir, India
    Am J Med 111:280-4. 2001
    ....
  28. ncbi Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada
    Nicole R Hartnell
    Dalhousie University, Halifax, Nova Scotia, Canada
    Am J Geriatr Pharmacother 2:171-80. 2004
    ..The COX-2SIs rofecoxib and celecoxib have been shown to be as effective as traditional NSAADs for pain relief, but with an improved GI safety profile...
  29. ncbi Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan
    Ikuya Miki
    Division of Diabetes, Digestive and Kidney Diseases, Department of Clinical Molecular Medicine, Kobe University School of Medicine, Kobe, Japan
    Eur J Gastroenterol Hepatol 15:27-33. 2003
    ..This report has ascertained which was more important, CPY2C19 polymorphism or antimicrobial susceptibility, when using 1-week lansoprazole-based or rabeprazole-based triple therapy in Japan...
  30. ncbi Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs
    Walter Smalley
    Vanderbilt University, Nashville, Tennessee 37232, USA
    Arthritis Rheum 46:2195-200. 2002
    ..To determine the frequency of use of recommended gastroprotective strategies in a cohort of patients receiving recurrent treatment with nonsteroidal antiinflammatory drugs (NSAIDs)...
  31. ncbi Chronic acid-related disorders are common and underinvestigated
    Sumit R Majumdar
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts 02215, USA
    Am J Gastroenterol 98:2409-14. 2003
    ....
  32. ncbi Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole
    J P Gisbert
    Department of Gastroenterology, University Hospital of La Princesa, Madrid, Spain
    Aliment Pharmacol Ther 13:1311-6. 1999
    ..A 'rescue' therapy with a quadruple combination of O, bismuth (B), tetracycline (T) and metronidazole (M) has been recommended...
  33. ncbi Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy)
    Jun ichi Yamao
    Third Department of Internal Medicine, Nara Medical University, 840 Shijocho, Kashihara 634 8512, Japan
    J Gastroenterol 41:1178-85. 2006
    ..In this study, we compare the effects of famotidine and rebamipide on NSAID-associated gastric mucosal lesions using upper gastrointestinal endoscopy...
  34. ncbi Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine
    Donald R Campbell
    Department of Medicine, VAMC, Kansas City, Missouri, USA
    Am J Gastroenterol 97:2208-14. 2002
    ..The purpose of this research was to determine the impact of pretreatment Helicobacter pylori infection on gastric ulcer healing rates in patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs) and antisecretory medications...
  35. ncbi Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects
    M Lazzaroni
    Gastrointestinal Unit, L. Sacco University Hospital, Milan, Italy
    Dig Liver Dis 33:S44-58. 2001
    ....
  36. ncbi Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial
    M J Kaviani
    Gastroenterohepatology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Iran
    Aliment Pharmacol Ther 17:211-6. 2003
    ..Endoscopic therapies and continuous intravenous omeprazole can decrease the morbidity and duration of hospital stay of patients with high-risk peptic ulcer...
  37. ncbi Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative
    M Kulig
    Institute of Social Medicine, Epidemiology, and Health Economics, Charite University Medical Center, Berlin, Germany
    Aliment Pharmacol Ther 18:767-76. 2003
    ..To determine the impact of gastro-oesophageal reflux disease (GERD) on the quality of life, to assess changes in the quality of life during treatment with esomeprazole and to define factors that can predict these changes...
  38. ncbi Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori
    Hassan Salman Roghani
    Department of Internal Medicine, Yazd University of Medical Sciences, Yazd, Iran
    J Gastroenterol Hepatol 18:778-82. 2003
    ..The aim of the present study was to assess the efficacy of two different doses of furazolidone in combination with amoxycillin and omeprazole...
  39. pmc Antileishmanial activity of the antiulcer agent omeprazole
    Suping Jiang
    Department of Biological Sciences, University of Cincinnati, Cincinnati, OH 45221 0006, USA
    Antimicrob Agents Chemother 46:2569-74. 2002
    ..Omeprazole deserves consideration as an alternative to currently available chemotherapeutics, which have severe toxic side effects...
  40. ncbi Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis
    Hashem B El-Serag
    Health Services Research Sections, Houston Center for Quality of Care and Utilization Studies, Department of Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA
    Arch Intern Med 162:2105-10. 2002
    ..Our objective in this study was to compare the cost-effectiveness of several strategies aimed at reducing the risk of clinical UGI events in NSAID users...
  41. ncbi Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease
    Karna Dev Bardhan
    Rotherham General Hospitals NHS Trust, Moorgate Road, Rotherham S60 2UD, United Kingdom
    Am J Gastroenterol 98:S40-8. 2003
    ..In clinical practice, the author has found these treatment strategies suitable for approximately 60% of newly diagnosed patients with GERD for the long-term management of symptomatic GERD of mild or moderate severity...
  42. ncbi Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications
    Kam Chuen Lai
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Am J Med 118:1271-8. 2005
    ..We compared the efficacy of a selective COX-2 inhibitor with that of proton pump inhibitor co-therapy in the reduction in the incidence of ulcer relapse in patients with a history of NSAID-related peptic ulcers...
  43. ncbi Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review
    Hans Joachim Ulmer
    IFE Institute for Research and Development, University Witten Herdecke GmbH, Witten, Germany
    Helicobacter 8:95-104. 2003
    ..However, a recent broad data review on the efficacy of the different regimens is missing. Therefore, the aim of this study was to systematically review the recent literature...
  44. pmc Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis
    M Yeo
    Genome Research Centre for Gastroenterology, Ajou University Medical Centre, San 5, Wonchon dong, Yeongtong Gu, Suwon, 442 749, Korea
    Gut 55:26-33. 2006
    ....
  45. ncbi Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer
    Christo J van Rensburg
    Gastroenterology Unit, Tygerberg Hospital, C7B, Room 1601, Tygerberg 7505, Capetown, Republic of South Africa
    Am J Gastroenterol 98:2635-41. 2003
    ..The present investigation aimed to establish a safe and, with regard to pH elevation, effective treatment that, based on in vitro evidence, should provide clinical benefit in this patient population...
  46. ncbi Healing properties of malabaricone B and malabaricone C, against indomethacin-induced gastric ulceration and mechanism of action
    Debashish Banerjee
    Department of Biochemistry, Dr B C Roy Post Graduate Institute of Basic Medical Sciences and IPGME and R, 244B, Acharya Jagadish Chandra Bose Road, Kolkata 700 020, India
    Eur J Pharmacol 578:300-12. 2008
    ....
  47. ncbi Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people
    Xiang Peng Hu
    Center of Endoscopic Diagnosis and Therapy, First Affiliated Hospital of Wenzhou Medical College, Wenzhou corrected China
    J Clin Pharm Ther 32:517-24. 2007
    ..To investigate whether the pharmacodynamics and pharmacokinetics of omeprazole (OPZ) are dependent of the CYP2C19 genotype status in Chinese people...
  48. ncbi Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?
    A S Tarnawski
    VA Medical Center, Long Beach, California, USA
    Dig Dis Sci 49:202-9. 2004
    ....
  49. ncbi Considerations for long-term use of proton-pump inhibitors
    W R Garnett
    School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298 0533, USA
    Am J Health Syst Pharm 55:2268-79. 1998
    ..Short- and long-term studies showed that PPIs have a wide safety margin and a favorable adverse-event profile with few drug interactions. Available data support the short- and long-term safety of PPIs...
  50. ncbi Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia
    N J Talley
    Department of Medicine, University of Sydney, Nepean Hospital, Penrith, NSW, Australia
    N Engl J Med 341:1106-11. 1999
    ..The relation between Helicobacter pylori infection and nonulcer dyspepsia is uncertain. We tested the hypothesis that curing the infection will relieve symptoms of dyspepsia...
  51. ncbi Asthma and gastroesophageal reflux disease: effect of long-term pantoprazole therapy
    Carlo Calabrese
    Department of Internal Medicine and Gastroenterology, Policlinico S Orsola Malpighi, Via Massarenti 9, 40138 Bologna, Italy
    World J Gastroenterol 11:7657-60. 2005
    ..To define the prevalence of gastroesophageal reflux disease (GERD) in mild persistent asthma and to value the effect of pantoprazole therapy on asthmatic symptoms...
  52. ncbi Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
    Kenneth R DeVault
    Department of Medicine, Mayo Clinic College of Medicine, Jacksonville, FL, USA
    Am J Gastroenterol 100:190-200. 2005
    ..Finally, there is a discussion of the rare patient with refractory GERD and a list of areas in need of additional study...
  53. ncbi Furazolidone combination therapies for Helicobacter pylori infection in the United States
    D Y Graham
    The VA Medical Center, Houston, Texas 77030, USA
    Aliment Pharmacol Ther 14:211-5. 2000
    ..Antibiotic resistance has begun to impair the ability to cure Helicobacter pylori infection...
  54. ncbi A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study
    J Labenz
    Medical Department, Ev Jung Stilling Krankenhaus, D 57074 Siegen, Germany
    Aliment Pharmacol Ther 21:739-46. 2005
    ..To assess the efficacy of the 8-week therapy with esomeprazole 40 mg vs. pantoprazole 40 mg for healing erosive oesophagitis (EE) as part of a management study...
  55. ncbi Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis
    C Faure
    Service de Gastro entérologie Pédiatrique, Hopital Robert Debre, Paris, France
    Aliment Pharmacol Ther 15:1397-402. 2001
    ..Data on the proton pump inhibitor lansoprazole in paediatric patients are limited...
  56. ncbi Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials
    J J Caro
    Division of General Internal Medicine, McGill University, Montreal, Quebec, Canada
    Clin Ther 23:998-1017. 2001
    ..The older proton pump inhibitor (PPI) omeprazole and the newer PPIs lansoprazole, rabeprazole, and pantoprazole are approved for the acute and maintenance treatment of gastroesophageal reflux disease (GERD)...
  57. ncbi Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know
    Malcolm Robinson
    Department of Medicine, Oklahoma Foundation for Digestive Research, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA
    Drugs 63:2739-54. 2003
    ..g. increased digoxin absorption or inability to absorb ketoconazole)...
  58. ncbi Low- versus high-dose azithromycin triple therapy for Helicobacter pylori infection
    W D Chey
    Department of Internal Medicine, University of Michigan, Ann Arbor, USA
    Aliment Pharmacol Ther 12:1263-7. 1998
    ..We report a clinical trial which evaluated the effectiveness of triple therapy containing low- and high-dose azithromycin to treat Helicobacter pylori infection...
  59. pmc Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus
    Pascual Parrilla
    Department of Surgery, University Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
    Ann Surg 237:291-8. 2003
    ..To compare the results of medical treatment and antireflux surgery in patients with Barrett's esophagus (BE)...
  60. pmc Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta
    T Watanabe
    Department of Biosignal Analysis, Osaka City University Medical School, Osaka 545 8585, Japan
    Gut 48:774-81. 2001
    ..Although gastric acid plays an important role in many types of gastric injuries, including peptic ulcer recurrence, the mechanism(s) remains unclear...
  61. ncbi Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection
    W M Wong
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    Aliment Pharmacol Ther 17:553-60. 2003
    ..To test the efficacy of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy for the second-line treatment of Helicobacter pylori infection...
  62. ncbi Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice
    Toshio Watanabe
    Department of Gastroenterology, Osaka City University Graduate School of Medicine, 1 4 3 Asahimachi, Abeno Ku, Osaka 545 8585, Japan
    Dig Dis Sci 50:S63-9. 2005
    ..In conclusion, rebamipide may accelerate gastric ulcer healing through both COX-2-dependent and COX-2-independent mechanisms...
  63. ncbi Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group
    N M Agrawal
    Department of Medicine, University of Connecticut Health Center, Farmington, USA
    Arch Intern Med 160:1455-61. 2000
    ..The usefulness of nonsteroidal anti-inflammatory drugs (NSAIDs) is limited by adverse gastrointestinal tract events...
  64. ncbi Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients?
    Elaine McColl
    Centre for Health Services Research, School of Population and Health Sciences, University of Newcastle upon Tyne, 21 Claremont Place, Newcastle upon Tyne NE2 4AA, United Kingdom
    Am J Gastroenterol 100:11-8. 2005
    ..This study aimed to determine the extent of agreement between clinicians and patients regarding assessments of reflux symptom severity in patients with gastroesophageal reflux disease...
  65. ncbi Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children
    Vasundhara Tolia
    Children s Hospital of Michigan, Detroit, Michigan 48201, USA
    J Pediatr Gastroenterol Nutr 35:S308-18. 2002
    ..In addition, the efficacy in healing of erosive esophagitis (EE) was determined in those children with EE who were enrolled in the study...
  66. ncbi Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study
    Basil I Hirschowitz
    Division of Gastroenterology and Hepatology, The University of Alabama at Birmingham, UAB Station, Birmingham, AL 35294 0007, USA
    Clin Gastroenterol Hepatol 3:39-48. 2005
    ..The aims of this study were to heal and prevent relapse of acid/peptic lesions during acid suppression and to analyze benefits and risks during long-term lansoprazole treatment...
  67. ncbi Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension
    Alessio Migneco
    Department of Medical Pathology, Catholic University, Rome, Italy
    Helicobacter 8:585-9. 2003
    ..The aim of our study was to determine the prevalence of H. pylori infection in hypertensive patients and the effects of H. pylori eradication on blood pressure and on digestive symptoms...
  68. ncbi Low-dose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication
    H Fakheri
    Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
    Aliment Pharmacol Ther 19:89-93. 2004
    ..Unfortunately, the usual dose of furazolidone is not tolerable in many patients. Lower doses of furazolidone are expected to cause fewer adverse effects...
  69. ncbi Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis
    Hyung Ran Yun
    The Hospital for Rheumatic Diseases, Department of Internal Medicine, Hanyang University College of Medicine, 133 792 Seoul, Korea
    Rheumatol Int 25:9-14. 2005
    ..Although COX-2 are the best option (among the strategies analyzed) to prevent GI toxicity, the incremental C/E ratio between COX-2 and no prophylaxis is higher than 50,000 dollar/QALY...
  70. ncbi Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease
    F Pace
    UO Gastroenterologia Ospedale Sacco, Milano, Italy
    Aliment Pharmacol Ther 22:349-56. 2005
    ..Quality of life has been assessed in a large, multicentre randomized, open label study...
  71. ncbi Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole
    A Pilotto
    Geriatric Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Aliment Pharmacol Ther 17:1399-406. 2003
    ..No placebo-controlled clinical trials have yet been published on the efficacy of therapy in older subjects with oesophagitis...
  72. ncbi On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial
    T Scholten
    Medizinische Klinik des Allgemeinen Krankenhauses Hagen, Hagen, Germany
    Digestion 72:76-85. 2005
    ..To compare safety and efficacy of on-demand pantoprazole 20 mg/40 mg versus placebo in the long-term management of patients with mild gastroesophageal reflux disease (GERD) after heartburn relief...
  73. ncbi Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis
    M B Fennerty
    Oregon Health and Science University, Portland, OR 97239 3098, USA
    Aliment Pharmacol Ther 21:455-63. 2005
    ..Secondary analyses from previous studies indicated that esomeprazole was more effective than lansoprazole and omeprazole in healing moderate or severe (Los Angeles grades C or D) erosive oesophagitis (EE)...
  74. ncbi Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease
    Suleiman Kaspari
    Private Practice, Luneburg, Germany
    Eur J Gastroenterol Hepatol 17:935-41. 2005
    ..Hence, on-demand treatment with pantoprazole 20 mg is safe and effective in maintaining control of the symptoms heartburn, acid regurgitation and pain on swallowing symptoms in patients with GORD grade 0/I with superiority to placebo...
  75. ncbi The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism
    M Kawamura
    Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
    Aliment Pharmacol Ther 17:965-73. 2003
    ..The acid suppressive effect of lansoprazole is influenced by the P450 2C19 (CYP2C19) polymorphism...
  76. ncbi Gastroprotective activity of Nigella sativa oil and its constituent, thymoquinone, against gastric mucosal injury induced by ischaemia/reperfusion in rats
    H S El-Abhar
    Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Kaser El Aini Street, 11562 Cairo, Egypt
    J Ethnopharmacol 84:251-8. 2003
    ..These results indicate that both N.O and TQ possess gastroprotective effect against gastric lesions which may be related to the conservation of the gastric mucosal redox state...
  77. ncbi Prevention of erosive oesophagitis relapse with pantoprazole
    J E Richter
    Department of Gastroenterology and Hepatology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Aliment Pharmacol Ther 20:567-75. 2004
    ..To compare the safety and efficacy of pantoprazole and ranitidine in maintaining erosive oesophagitis healing...
  78. ncbi A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease
    A Norman Hansen
    Harbitzallèen Legesenter, Oslo, Norway
    Int J Clin Pract 59:665-71. 2005
    ..2%) and esomeprazole on-demand (75.4%) than with ranitidine continuous (33.5%) treatment (p < 0.0001). More patients were kept in remission, symptom free and were overall more satisfied with esomeprazole treatment than ranitidine...
  79. ncbi Systematic review: Helicobacter pylori infection and impaired drug absorption
    E Lahner
    Digestive and Liver Disease Unit, 2nd Medical School, University La Sapienza, Rome, Italy
    Aliment Pharmacol Ther 29:379-86. 2009
    ..Impaired acid secretion may affect drug absorption and may be consequent to corporal Helicobacter pylori-gastritis, which may affect the absorption of orally administered drugs...
  80. ncbi Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis
    Donald O Castell
    Department of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston 29425, USA
    Am J Gastroenterol 97:575-83. 2002
    ..This study compared esomeprazole with lansoprazole for the healing of erosive esophagitis and resolution of heartburn...
  81. ncbi Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions
    D C Metz
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Aliment Pharmacol Ther 23:437-44. 2006
    ..Zollinger-Ellison syndrome and idiopathic hypersecretion are gastrointestinal hypersecretory conditions requiring long-term maintenance...
  82. ncbi Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine
    S D Mathias
    The Lewin Group, San Francisco, California 94107, USA
    Dig Dis Sci 46:2416-23. 2001
    ..Patients taking lansoprazole 15 or 30 mg daily reported better outcomes than those receiving ranitidine 150 twice a day over the eight-week study...
  83. ncbi Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors
    James M Scheiman
    Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Am J Gastroenterol 101:701-10. 2006
    ..Such studies are particularly relevant, given that concerns regarding adverse cardiovascular outcomes among COX-2 inhibitor users may prompt re-evaluation of their use...
  84. ncbi Association between antidepressant use and prescribing of gastric acid suppressants
    Janice Ma
    Canadian Forces Health Services, Ottawa, Ontario
    Can J Psychiatry 51:178-84. 2006
    ..To determine whether an increased risk of gastrointestinal events is present in younger, generally healthy adults who consume antidepressants...
  85. ncbi Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease
    Vasundhara Tolia
    Division of Pediatric Gastroenterology and Hepatology, Children s Hospital of Michigan, Detroit, MI, USA
    J Pediatr Gastroenterol Nutr 42:384-91. 2006
    ....
  86. ncbi Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients
    T Stupnicki
    General Hospital Graz West, Department of Gastroenterology, Graz, Austria
    Digestion 68:198-208. 2003
    ..i.d.), administered for 6 months to rheumatic patients who required long-term therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and who were at increased risk of developing gastrointestinal lesions...
  87. ncbi Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine
    Cristina Pozzoli
    Department of Human Anatomy, Pharmacology and Forensic Medicine, University of Parma, Via Volturno 39, Parma, Italy
    Naunyn Schmiedebergs Arch Pharmacol 374:283-91. 2007
    ..The intestinal protection, possibly related to antioxidant and anti-inflammatory properties of these drugs, may suggest new therapeutic uses of PPIs in intestinal inflammatory diseases...
  88. ncbi Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis
    L Lundell
    Department of Surgery, Karolinska University Hospital, Stockholm, Sweden
    Br J Surg 94:198-203. 2007
    ..This randomized clinical trial compared long-term outcome after antireflux surgery with acid inhibition therapy in the treatment of chronic gastro-oesophageal reflux disease (GORD)...
  89. ncbi Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators
    P J Kahrilas
    Department of Gastroenterology and Hepatology, Northwestern University Medical School, Chicago, IL 60611 3008, USA
    Aliment Pharmacol Ther 14:1249-58. 2000
    ..The pharmacologic profile of the new proton pump inhibitor esomeprazole has demonstrated advantages over omeprazole that suggest clinical benefits for patients with acid-related disease...
  90. ncbi The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials
    A Rostom
    Department of Medicine, University of Ottawa, Ontario, Canada
    J Rheumatol 27:2203-14. 2000
    ..To review the effectiveness of common interventions for the prevention of nonsteroidal antiinflammatory drug (NSAID) induced upper gastrointestinal (GI) toxicity...
  91. ncbi Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole
    P O Katz
    Oesophageal Research Laboratory, Department of Medicine, The Graduate Hospital, Phiadelphia, Pennsylvania 19146, USA
    Aliment Pharmacol Ther 14:709-14. 2000
    ..Nocturnal acid breakthrough, defined as gastric pH < 4.0 continuously for > 60 min, may compromise treatment goals in patients with GERD...
  92. ncbi Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer
    R Dani
    Department of Pathology of the School of Medicine of the Federal University of Minas Gerais, Belo Horizonte, Brazil
    Aliment Pharmacol Ther 13:1647-52. 1999
    ..To evaluate the efficacy of omeprazole plus clarithromycin and furazolidone in Helicobacter pylori eradication and duodenal ulcer healing in Brazilian patients...
  93. ncbi Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial
    Akira Terano
    Department of Gastroenterology, Dokkyo University School of Medicine, Tochigi, Japan
    J Gastroenterol 42:690-3. 2007
    ..We examined the efficacy of rebamipide in gastric ulcer healing following 1 week of eradication therapy in a randomized, double-blind, placebo-controlled trial...
  94. ncbi A glass of water immediately increases gastric pH in healthy subjects
    George Karamanolis
    Hepatogastroenteroly Unit, 2nd Department of Internal Medicine Propaedeutic, Attikon University General Hospital, Athens University, Athens, Greece
    Dig Dis Sci 53:3128-32. 2008
    ..Onset of action of antisecretory agents is of pivotal importance for patients with gastroesophageal reflux disease (GERD) treated "on-demand."..
  95. ncbi Long-term management of patients with symptoms of gastro-oesophageal reflux disease -- a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practi
    A N Hansen
    Harbitzallèen Legesenter, Oslo, Norway
    Int J Clin Pract 60:15-22. 2006
    ..In conclusion, esomeprazole 20 mg once daily continuously and on-demand were more effective than ranitidine continuously for maintaining QoL...
  96. ncbi Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease
    D A Revicki
    Center for Health Outcomes Research, MEDTAP International, Bethesda, MD 20814, USA
    Aliment Pharmacol Ther 13:1621-30. 1999
    ..We evaluated the association between complete resolution of heartburn symptoms and functioning and well-being in three samples of patients with GERD...
  97. ncbi Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection
    D Boixeda
    Department of Gastroenterology, Ramon y Cajal Hospital, University of Alcala, Madrid, Spain
    Aliment Pharmacol Ther 16:1457-60. 2002
    ..To study the efficacy of a 7-day quadruple regimen combining pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection after failure of standard triple therapy...
  98. ncbi Oral administration of geranylgeranylacetone improves survival rate in a rat endotoxin shock model: administration timing and heat shock protein 70 induction
    Junya Nakada
    Division of Medical Biochemistry, Tottori University Faculty of Medicine, Yonago 683 8503, Japan
    Shock 24:482-7. 2005
    ....
  99. ncbi Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin, and secnidazole for Helicobacter pylori eradication in peptic ulcer
    Fernando Marcuz Silva
    Department of Clinical Gastroenterology, Hospital das Clinicas, Faculty of Medicine, University of Sao Paulo
    Rev Hosp Clin Fac Med Sao Paulo 57:9-14. 2002
    ..To determine the eradication rate of an ultra-short treatment schedule for Helicobacter pylori infection in a population with peptic ulcers, using omeprazole, secnidazole, and azithromycin in a once-daily dose for 3 days...
  100. ncbi Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents
    Katherine F Croom
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2129-35; discussion 2136-7. 2005
    ..Lansoprazole was generally well tolerated in children and adolescents, with the most common treatment-related adverse events being gastrointestinal events and headache...
  101. ncbi A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine
    W Z Liu
    Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Second Medical University, China
    Aliment Pharmacol Ther 14:1519-22. 2000
    ..In our previous study, a triple therapy using tripotassium dicitrato bismuthate (TDB), josamycin and furazolidone achieved a suboptimal cure rate of Helicobacter pylori infection...

Research Grants30

  1. THE ROLE OF MYCOBACTERIA IN CROHN'S DISEASE
    David Graham; Fiscal Year: 2005
    ..The results of this study should either confirm or refute the proposed etiologic association of M. paratuberculosis and Crohn's disease as well as the identification of patients with Crohn's disease and M. paratuberculosis. ..
  2. Surveillance for Hepatocellular Carcinoma among HCV-infected Veterans
    Hashem El Serag; Fiscal Year: 2009
    ..Evaluating the extent and patterns of HCC surveillance is crucial in understanding diffusion (and obstacles) of this practice and in designing interventions to improve the implementation of HCC surveillance. ..
  3. Gene Expression in Barrett's Esophagus
    Hashem El Serag; Fiscal Year: 2006
    ..We present preliminary data on microarray and RT-PCRanalyses on 5 patients with BE that suggest an overactive Wnt pathway: we have also assembled the essential components of a successful study using microarrays. ..
  4. Epidemiologic Case-control Study of Barrett's Esophagus
    Nicholas Shaheen; Fiscal Year: 2005
    ..Finally, by comparing subjects with Barrett's to controls with reflux, and controlling for severs of reflux, the impact of a Barrett's diagnosis on quality of life and psychological stress may be seen. ..
  5. Defintion of the Physiological Properties of GIP
    Michael Wolfe; Fiscal Year: 2007
    ..abstract_text> ..
  6. NOVEL THERAPIES FOR ACETAMINOPHEN TOXICITY
    Laura James; Fiscal Year: 2004
    ..abstract_text> ..
  7. The Perception of Cancer Risk in Patients with Barrett's Esophagus
    Nicholas Shaheen; Fiscal Year: 2007
    ..The resultant study application will assess health-related quality of life, health-related anxiety and healthcare utilization as outcomes. [unreadable] [unreadable]..
  8. GASTRIC ENTEROCHROMAFFIN-LIKE CELL IN ULCER DISEASE
    George Sachs; Fiscal Year: 2005
    ..Hence this approach will provide additional insights into mechanisms of regulation of gastric secretion and enable illuminated interpretation of the pathophysiology of peptic ulcer disease. ..
  9. Role of Gastrin in the Pathogenesis of Colorectal Cancer
    Michael Wolfe; Fiscal Year: 2008
    ..The answers to these provocative hypotheses can only be achieved by gaining a thorough understanding of the molecular mechanisms by which gastrin exerts its trophic properties. ..
  10. THE GASTRIC ACID PUMP AS A TARGET FOR ULCER TREATMENT
    George Sachs; Fiscal Year: 2009
    ..The results of the proposed research will further improve the agents used for the treatment of acid-related diseases and also our knowledge of the ATPase and cellular events involved in regulation of its activity. ..
  11. Evaluation of a Biomarker for Acetaminophen Toxicity
    Laura James; Fiscal Year: 2005
    ..The data generated from this study will lead to enhanced recognition of APAP hepatotoxicity, thus allowing for better identification of "at risk" populations and the creation of prevention strategies. ..
  12. Risk factors for gastric disease in pediatric H. pylori
    Benjamin Gold; Fiscal Year: 2006
    ..We propose to further our previous work with critically lacking studies from a multivariate approach leading to a better understanding of the gastroduodenal disease sequelae and overall pathobiology of Hp infection in humans. ..
  13. HEALTH EFFECTS OF ACUTE H PYLORI INFECTION IN CHILDREN
    Douglas Passaro; Fiscal Year: 2003
    ..abstract_text> ..
  14. The CASCADE Study: End-of-Life in Advanced Dementia
    Susan Mitchell; Fiscal Year: 2008
    ..abstract_text> ..
  15. The ADEPT Study: Estimating Prognosis in Advanced Dementia
    Susan Mitchell; Fiscal Year: 2009
    ..Thus, the information derived from this study has the potential to make important clinical, research and policy-relevant contributions to the care of older persons with dementia at the end-of-life. ..
  16. Host-Response Relationships in Patients with Candidemia
    Melissa Johnson; Fiscal Year: 2006
    ....
  17. Reflux Disease in Patients with Throat Signs/Symptoms
    Michael Vaezi; Fiscal Year: 2005
    ..These methods will be employed pre- and post-therapy on all patients to assess their potential clinical utility, especially in those unresponsive to medical therapy after aggressive acid suppression. ..
  18. Barrett's Esophagus Ablation with Celocoxib Trial
    Charles Lightdale; Fiscal Year: 2002
    ..Patients will be accrued during the first study year, and will be followed until the last patient enrolled completes one year of treatment. ..
  19. Tube-feeding in Elderly: Decision-making and Outcomes
    Susan Mitchell; Fiscal Year: 2003
    ..By the end of the award period the applicant will have the skills, experience and research track record necessary to become an independent investigator and leader in academic geriatrics. ..
  20. CANCER CHEMOPREVENTION--ROLE OF INFECTION/IMMUNITY
    Charles Loprinzi; Fiscal Year: 2003
    ..abstract_text> ..
  21. A MICROSURGICAL INVESTIGATION OF GASTRIC ACID SECRETION
    John Geibel; Fiscal Year: 2004
    ..abstract_text> ..
  22. VISUAL ADAPTATION IN THE VERTEBRATE RETINA
    Harris Ripps; Fiscal Year: 2005
    ....
  23. MII to characterize reflux in Barrett's esophagus
    Donald Castell; Fiscal Year: 2005
    ....
  24. Role of Infectious Agents in Pediatric Crohn's Disease
    Benjamin Gold; Fiscal Year: 2005
    ..Subsequent prospective application of methods and systems developed by this proposal to the uniquely large, well characterized Consortium cohort will optimize detecting differences between CD and non-disease...
  25. P-glycoprotein and Steroid-Resistant Nephrotic Syndrome
    LYNDA WELAGE; Fiscal Year: 2005
    ..abstract_text> ..
  26. Pathologic Markers of Genetic Damage and Disease in IBD
    Melvin Heyman; Fiscal Year: 2005
    ..abstract_text> ..
  27. Gap-Junction-Medicated Cell Death in Rod-Cone Dystrophie
    Harris Ripps; Fiscal Year: 2006
    ..abstract_text> ..
  28. ASTHMA CLINICAL RESEARCH NETWORK
    Emily Dimango; Fiscal Year: 2002
    ....
  29. Comparative effectiveness of environmental intervention and standard care in abil
    Emily Dimango; Fiscal Year: 2010
    ..Results of the study have the potential to affect public health policy as well as reimbursement from third party health care insurance companies. PHS 398/2590 (Rev. 11/07) Page Continuation Format Page ..